Dr Peters current work is focused on use of different antihypertensives, frailty and risk and benefit of treatment in the very elderly.
Between 2010 and 2012 Dr Peters was part of the core team setting up and developing the Imperial Clinical Trials Unit (ICTU). ICTU was launched in 2010 and is a fully UKCRC registered trials unit.
Prior to 2010 she led the multinational HYpertension in the Very Elderly Trial Cognitve function (HYVET-COG) study and co-ordinated the main Hypertension in the Very Elderly [HYVET] trial. HYVET was an Imperial sponsored multinational double blind RCT which was rated ‘Trial of the year’ by the Society for Clinical Trials and an exceptional landmark in medicine(F1000) in 2008. The HYVET trial results have changed global guidelines for the use of antihypertensive treatment in older adults (>=80 years).
Research interests include risk factors for dementia, particularly cardiovascular risk factors and potential interventions to ameliorate or prevent cognitive decline and dementia.
Anstey KJ, Peters R, 2018, Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research., J Prev Alzheimers Dis, Vol:5, Pages:2-4
Mortby ME, Peters R, 2018, Greater cognitive decline relative to normal ageing occurs at least 10 years prior to clinical dementia diagnosis., Bmj Evid Based Med, Vol:23
et al., 2018, Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study., Int Psychogeriatr, Pages:1-10
et al., 2018, Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study, Alzheimers & Dementia, Vol:14, ISSN:1552-5260, Pages:280-292
et al., 2018, More evidence is needed. Iron, incident cognitive decline and dementia: a systematic review, Therapeutic Advances in Chronic Disease, ISSN:2040-6223